Autolus raises sales guidance, secures $75M credit facility
LONDON and GAITHERSBURG, Md. - Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for AUCATZYL and raised its full-year sales guidance to $140 million to $150 million from $120 million to $135 million, according to a press release statement issued today.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
LONDON and GAITHERSBURG, Md. - Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for AUCATZYL and raised its full-year sales guidance to $140 million to $150 million from $120 million to $135 million, according to a press release statement issued today. The company reported a gross margin of approximately 35% for the first half of 2026, compared to a negative gross margin of approximately 20% in the second half of 2025. Second quarter sales increased approximately 70% over the first quarter of 2026 and more than 100% compared to the second quarter of 2025.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- LONDON and GAITHERSBURG, Md. - Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for AUCATZYL and raised its full-year sales guidance to $140 million to $150 million from $120 million to $135 million, according to a press release statement issued today.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 4m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Autolus raises sales guidance, secures $75M credit facility
Sources1TypeCoverageInvesting.com · Company News